323 related articles for article (PubMed ID: 30287350)
1. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F
Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350
[TBL] [Abstract][Full Text] [Related]
2. French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies.
Bouvard B; Confavreux CB; Briot K; Bonneterre J; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Kerbrat P; Lespessailles E; Lesur A; Mayeur D; Paccou J; Trémollières F; Vieillard MH; Debiais F
Joint Bone Spine; 2019 Oct; 86(5):542-553. PubMed ID: 31352137
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
James H; Aleksic I; Bienz MN; Pieczonka C; Iannotta P; Albala D; Mariados N; Mouraviev V; Saad F
Urology; 2014 Jul; 84(1):164-8. PubMed ID: 24976229
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
5. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
6. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
Adler RA; Hastings FW; Petkov VI
Osteoporos Int; 2010 Apr; 21(4):647-53. PubMed ID: 19533207
[TBL] [Abstract][Full Text] [Related]
7. 2018 update of French recommendations on the management of postmenopausal osteoporosis.
Briot K; Roux C; Thomas T; Blain H; Buchon D; Chapurlat R; Debiais F; Feron JM; Gauvain JB; Guggenbuhl P; Legrand E; Lehr-Drylewicz AM; Lespessailles E; Tremollieres F; Weryha G; Cortet B
Joint Bone Spine; 2018 Oct; 85(5):519-530. PubMed ID: 29654947
[TBL] [Abstract][Full Text] [Related]
8. [Osteoporosis in castration therapy--a neglected field].
Bratt O; Akesson K
Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
[No Abstract] [Full Text] [Related]
9. French recommendations on the prevention and treatment of osteoporosis secondary to bariatric surgery.
Paccou J; Genser L; Lespessailles É; Bertin É; Javier RM; Duclos M; Joly AS; Boirie Y; Pattou F; Delarue J; Cortet B
Joint Bone Spine; 2022 Nov; 89(6):105443. PubMed ID: 35908644
[TBL] [Abstract][Full Text] [Related]
10. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
Smith MR
Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
[TBL] [Abstract][Full Text] [Related]
13. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.
Poon Y; Pechlivanoglou P; Alibhai SMH; Naimark D; Hoch JS; Papadimitropoulos E; Hogan ME; Krahn M
BJU Int; 2018 Jan; 121(1):17-28. PubMed ID: 28921820
[TBL] [Abstract][Full Text] [Related]
15. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
16. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
19. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate.
Bae DC; Stein BS
J Urol; 2004 Dec; 172(6 Pt 1):2137-44. PubMed ID: 15538219
[TBL] [Abstract][Full Text] [Related]
20. Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer.
Chang SS
Urology; 2003 Dec; 62(6 Suppl 1):29-35. PubMed ID: 14706506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
